| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from reinstatement of merger agreement related party | - | 0 |
| Net cash, cash equivalents and restricted cash provided by financing activities | 2,181 | 2,425 |
| Net change in cash, cash equivalents and restricted cash | 99 | 7 |
| Cash and cash equivalents at beginning of period | 741 | - |
| Cash and cash equivalents at end of period | 840 | - |
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)